A class action settlement has been reached for consumers who purchased generic valsartan blood pressure medication manufactured by Hetero Labs that was contaminated with NDMA, a cancer-causing chemical. The contaminated pills were sold between May and July 2018. Claim forms are expected to become available by April 2, 2026, with a filing deadline of June 2, 2026.
Status: Claim Forms Coming April 2026 | Claim Deadline: June 2, 2026 | Payout: Economic Loss Refund
What Is This Settlement About?
The settlement resolves claims that Hetero Labs manufactured generic valsartan using a process (“Hetero Process III”) that introduced NDMA contamination into the active pharmaceutical ingredient. NDMA (N-Nitrosodimethylamine) is classified as a probable human carcinogen. The contaminated valsartan was recalled, but consumers had already been exposed during the May–July 2018 period.
Who Is Eligible?
Individuals and third-party payors (such as insurance companies) in the United States who purchased valsartan formulations made with Hetero Process III active ingredient between May 1, 2018 and July 31, 2018. Check your prescription bottle for the manufacturer name or contact your pharmacy to confirm whether your valsartan was manufactured by Hetero Labs or Camber Pharmaceuticals.
How Much Can You Receive?
The exact settlement amount has not been publicly disclosed. Payments are structured as economic loss refunds — reimbursement for what you paid for the contaminated medication. The final amount per claimant will depend on the total settlement fund, number of valid claims, and administrative costs.
How to File a Claim
Claim forms will be available through a dedicated settlement website launching by April 2, 2026. Claims can be submitted online or mailed to the Settlement Administrator (EAG Gulf Coast, LLC). The filing deadline is June 2, 2026.
Important Dates
- Claim Forms Available: By April 2, 2026
- Claim Filing Deadline: June 2, 2026
- Opt-Out Deadline: June 2, 2026
- Final Approval Hearing: June 30, 2026 at 10:00 AM (Camden, NJ)
Case Details
| Case Name | In Re: Valsartan, Losartan, and Irbesartan Products Liability Litigation |
| MDL Number | 19-MD-2875 |
| Court | U.S. District Court, District of New Jersey |
| Judge | Hon. Renee M. Bumb |
| Defendants | Hetero Drugs Ltd., Hetero Labs Ltd., Hetero USA Inc., Camber Pharmaceuticals Inc. |
Frequently Asked Questions
How do I know if my valsartan was contaminated?
Check your prescription bottle for the manufacturer name. If it lists Hetero Labs or Camber Pharmaceuticals, and you filled the prescription between May and July 2018, you may be eligible. You can also contact your pharmacy for confirmation.
Is the claim form available now?
Not yet. The settlement website and claim forms are expected to launch by April 2, 2026.
View the Valsartan blood pressure settlement details on OpenClassActions.com.
By Steve Levine | Published: February 26, 2026
Please submit only truthful information. OpenClassActions.org is a consumer news site and is not a settlement administrator or a law firm.